Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas

Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low‐grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated wi...

Full description

Saved in:

Bibliographic Details
Published in	Annals of neurology Vol. 58; no. 2; pp. 322 - 326
Main Authors	Kujas, Michèle, Lejeune, Julie, Benouaich-Amiel, Alexandra, Crinière, Emmanuelle, Laigle-Donadey, Florence, Marie, Yannick, Mokhtari, Karima, Polivka, Marc, Bernier, Michèle, Chretien, Fabrice, Couvelard, Anne, Capelle, Laurent, Duffau, Hugues, Cornu, Philippe, Broët, Philippe, Thillet, Joëlle, Carpentier, Antoine F., Sanson, Marc, Hoang-Xuan, Khê, Delattre, Jean-Yves
Format	Journal Article
Language	English
Published	Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2005 Willey-Liss
Subjects	Adolescent Adult Aged Antineoplastic agents Biological and medical sciences Brain Neoplasms - genetics Brain Neoplasms - pathology Chemotherapy Chromosome Deletion Chromosomes, Human, Pair 1 Chromosomes, Human, Pair 19 Female Glioma - genetics Glioma - pathology Humans Immunohistochemistry - methods Loss of Heterozygosity Male Medical sciences Middle Aged Molecular Biology - methods Neurology Pharmacology. Drug treatments Tumors of the nervous system. Phacomatoses Tumor Chromosome Nervous system diseases Prognosis Glioma Central nervous system disease
Online Access	Get full text
ISSN	0364-5134 1531-8249
DOI	10.1002/ana.20543

Cover

Abstract	Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low‐grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression‐free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression‐free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low‐grade gliomas. Ann Neurol 2005;58:322–326
AbstractList	Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor ( EGFR ) gene amplification, and p53 expression was performed in a series of 131 low‐grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression‐free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression‐free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low‐grade gliomas. Ann Neurol 2005;58:322–326 Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low-grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression-free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression-free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low-grade gliomas. Ann Neurol 2005; 58:322-326 Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low-grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression-free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression-free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low-grade gliomas.Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low-grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression-free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression-free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low-grade gliomas. Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was performed in a series of 131 low-grade gliomas. The profile of molecular changes, clinical findings, and histology were subsequently correlated with the course of the disease, mainly progression-free survival. When these parameters were considered as candidate variables in a multivariate analysis, only loss of heterozygosity on chromosome 1p was associated with increased progression-free survival (hazard ratio, 0.521), indicating a major favorable prognostic role of this genetic alteration in low-grade gliomas.
Author	Marie, Yannick Duffau, Hugues Lejeune, Julie Capelle, Laurent Broët, Philippe Kujas, Michèle Hoang-Xuan, Khê Sanson, Marc Benouaich-Amiel, Alexandra Crinière, Emmanuelle Carpentier, Antoine F. Bernier, Michèle Cornu, Philippe Laigle-Donadey, Florence Mokhtari, Karima Delattre, Jean-Yves Chretien, Fabrice Couvelard, Anne Polivka, Marc Thillet, Joëlle
Author_xml	– sequence: 1 givenname: Michèle surname: Kujas fullname: Kujas, Michèle organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 2 givenname: Julie surname: Lejeune fullname: Lejeune, Julie organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 3 givenname: Alexandra surname: Benouaich-Amiel fullname: Benouaich-Amiel, Alexandra organization: Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, France – sequence: 4 givenname: Emmanuelle surname: Crinière fullname: Crinière, Emmanuelle organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 5 givenname: Florence surname: Laigle-Donadey fullname: Laigle-Donadey, Florence organization: Service de Neurologie Mazarin, Groupe Hospitalier Pitié-Salpêtrière, France – sequence: 6 givenname: Yannick surname: Marie fullname: Marie, Yannick organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 7 givenname: Karima surname: Mokhtari fullname: Mokhtari, Karima organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 8 givenname: Marc surname: Polivka fullname: Polivka, Marc organization: Service d'anatomopathologie, Hôpital Lariboisière, Paris, France – sequence: 9 givenname: Michèle surname: Bernier fullname: Bernier, Michèle organization: Service d'anatomopathologie, Hôpital Foch, Suresnes, France – sequence: 10 givenname: Fabrice surname: Chretien fullname: Chretien, Fabrice organization: Service d'anatomopathologie, Hôpital Henri Mondor, Créteil, France – sequence: 11 givenname: Anne surname: Couvelard fullname: Couvelard, Anne organization: Service d'anatomopathologie, Hôpital Beaujon, Clichy, France – sequence: 12 givenname: Laurent surname: Capelle fullname: Capelle, Laurent organization: Service de Neurochirurgie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France – sequence: 13 givenname: Hugues surname: Duffau fullname: Duffau, Hugues organization: Service de Neurochirurgie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France – sequence: 14 givenname: Philippe surname: Cornu fullname: Cornu, Philippe organization: Service de Neurochirurgie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France – sequence: 15 givenname: Philippe surname: Broët fullname: Broët, Philippe organization: INSERM U472, Hôpital Paul Brousse, Villejuif, France – sequence: 16 givenname: Joëlle surname: Thillet fullname: Thillet, Joëlle organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 17 givenname: Antoine F. surname: Carpentier fullname: Carpentier, Antoine F. organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 18 givenname: Marc surname: Sanson fullname: Sanson, Marc organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 19 givenname: Khê surname: Hoang-Xuan fullname: Hoang-Xuan, Khê organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France – sequence: 20 givenname: Jean-Yves surname: Delattre fullname: Delattre, Jean-Yves email: jean-yves.delattre@psl.ap-hop-paris.fr organization: INSERM U711 et Université Pierre et Marie Curie Paris VI, France
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17082262$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16049942$$D View this record in MEDLINE/PubMed
BookMark	eNqF0U1LXDEUBuAgFh21i_6BcjctdHE1X_cj3Q1DdUqtbhShm3CSm4zR3JsxuVPrv2_sjBUK1lXg8LyH8J49tD2EwSD0juBDgjE9ggEOKa4420ITUjFStpSLbTTBrOZlRRjfRXsp3WCMRU3wDtolNeZCcDpBx7PrGPqQQm8Ksix8SOlzMS0s_AwRlDfFMobFENLodB7qMcTCDZndl4sInSkW3oUe0gF6Y8En83bz7qPL4y8Xs3l5en7ydTY9LTWnlJWaCmsUaGZVo5jSmJquUVQLqzoqKOZYCaOtzUBUhFsNHeOMd6btiOhqxvbRx_Xe_K27lUmj7F3SxnsYTFglWbecsVzJq5A0jOem2gzfb-BK9aaTy-h6iA_yqaIMPmwAJA3eRhi0S8-uwS2l9aP7tHY65hKjsc8Ey8czyXwm-edM2R79Y7UbYXRhGCM4_7_EvfPm4eXVcno2fUqU64RLo_n1NwHxVtYNayp5dXYi62_fxXz-g8mK_Qa5ILFY
CODEN	ANNED3
CitedBy_id	crossref_primary_10_1097_NEN_0b013e31819ed0b7 crossref_primary_10_1371_journal_pone_0032764 crossref_primary_10_1111_j_1468_1331_2010_03151_x crossref_primary_10_1038_s41419_024_06486_z crossref_primary_10_1111_cns_12148 crossref_primary_10_1002_psp4_54 crossref_primary_10_1007_s11060_013_1106_6 crossref_primary_10_1016_j_clineuro_2008_06_020 crossref_primary_10_1016_j_clineuro_2012_07_002 crossref_primary_10_1007_s00381_024_06504_7 crossref_primary_10_1016_j_brainres_2008_01_027 crossref_primary_10_1016_j_jns_2010_11_024 crossref_primary_10_1093_neuonc_nop002 crossref_primary_10_1212_01_wnl_0000229927_12007_37 crossref_primary_10_1093_neuonc_nor185 crossref_primary_10_1016_j_wneu_2023_02_099 crossref_primary_10_1016_j_neurol_2008_04_002 crossref_primary_10_1002_ana_21044 crossref_primary_10_1007_s11060_008_9563_z crossref_primary_10_3390_ijms10010184 crossref_primary_10_1200_JCO_2006_05_9238 crossref_primary_10_1002_cncr_22211 crossref_primary_10_1007_s11060_008_9600_y crossref_primary_10_1016_j_hoc_2012_05_001 crossref_primary_10_3171_2012_12_FOCUS12283 crossref_primary_10_1007_s11060_013_1103_9 crossref_primary_10_1097_NEN_0b013e31820681aa crossref_primary_10_1007_s12035_015_9523_5 crossref_primary_10_1227_NEU_0b013e31820b522a crossref_primary_10_1097_CCO_0b013e3282f075f3 crossref_primary_10_1007_s11547_013_0347_y crossref_primary_10_1007_s13402_019_00447_x crossref_primary_10_1212_WNL_0b013e3181f96282 crossref_primary_10_1007_s11060_012_0831_6 crossref_primary_10_1093_neuonc_not092 crossref_primary_10_1016_j_canlet_2016_01_024 crossref_primary_10_1007_s00701_009_0232_6 crossref_primary_10_1007_s11060_008_9680_8 crossref_primary_10_1186_s12967_014_0288_9 crossref_primary_10_1093_neuonc_nor205 crossref_primary_10_3233_CBM_171177 crossref_primary_10_1212_01_wnl_0000262034_26310_a2 crossref_primary_10_1093_neuonc_not145 crossref_primary_10_1007_s11060_006_9168_3 crossref_primary_10_3389_fncel_2021_704344 crossref_primary_10_1097_01_cco_0000245322_11787_72 crossref_primary_10_1111_nan_12246 crossref_primary_10_1097_NEN_0b013e3182901f41 crossref_primary_10_1002_ana_21125 crossref_primary_10_1111_j_1365_2990_2008_01002_x crossref_primary_10_3171_2012_11_JNS121100 crossref_primary_10_1111_j_1750_3639_2010_00447_x crossref_primary_10_1093_jnci_djk135 crossref_primary_10_1016_j_semradonc_2015_02_008 crossref_primary_10_1016_j_ejca_2010_11_031 crossref_primary_10_1212_01_wnl_0000319721_98502_1b crossref_primary_10_1007_s11060_014_1526_y crossref_primary_10_1002_ijc_23270 crossref_primary_10_1007_s11060_010_0490_4 crossref_primary_10_1016_j_wneu_2019_06_169 crossref_primary_10_1007_s11910_006_0008_9 crossref_primary_10_1111_j_1440_1789_2008_00863_x crossref_primary_10_1016_j_jocn_2020_03_037 crossref_primary_10_1684_bdc_2009_1019
Cites_doi	10.1002/path.837 10.1016/S0002-9440(10)64183-1 10.1007/s00401-004-0861-z 10.1093/jnen/60.9.863 10.1097/00005072-199710000-00003 10.1016/S0360-3016(96)00352-5 10.1200/JCO.2004.10.169 10.1200/JCO.2002.08.121 10.1200/JCO.2002.09.126 10.1016/S0360-3016(01)02692-X
ContentType	Journal Article
Copyright	Copyright © 2005 American Neurological Association 2005 INIST-CNRS
Copyright_xml	– notice: Copyright © 2005 American Neurological Association – notice: 2005 INIST-CNRS
DBID	BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7X8
DOI	10.1002/ana.20543
DatabaseName	Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic
DatabaseTitleList	CrossRef Neurosciences Abstracts MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1531-8249
EndPage	326
ExternalDocumentID	16049942 17082262 10_1002_ana_20543 ANA20543 ark_67375_WNG_6KM9HHZ3_5
Genre	shortCommunication Research Support, Non-U.S. Gov't Journal Article Comparative Study
GrantInformation_xml	– fundername: Fondation de France funderid: 2002008957 – fundername: Délégation à la Recherche Clinique funderid: AP‐HP; MUL03012 – fundername: Ligue nationale contre le cancer
GroupedDBID	--- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OB 1OC 1ZS 23M 2QL 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEJM AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABIVO ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBMB ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFAZI AFBPY AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHMBA AI. AIACR AIAGR AIDQK AIDYY AIQQE AITYG AIURR AJJEV ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P F8P FEDTE FUBAC FYBCS G-S G.N GNP GODZA GOZPB GRPMH H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KBYEO KD1 KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LXL LXN LXY LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.- Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI UB1 V2E V8K V9Y VH1 W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR X7M XG1 XJT XPP XSW XV2 YOC YQJ ZGI ZRF ZRR ZXP ZZTAW ~IA ~WT ~X8 AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION IQODW ACRZS AEUQT AFPWT CGR CUY CVF ECM EIF NPM RWD RWI WRC WUP 7TK 7X8
ID	FETCH-LOGICAL-c4223-c29febac3fb7b3bc02ed7b2c9fbd292040b9ecffc3f9514fcad3434de8d19d633
IEDL.DBID	DR2
ISSN	0364-5134
IngestDate	Fri Sep 05 13:23:54 EDT 2025 Fri Sep 05 11:23:47 EDT 2025 Wed Feb 19 01:53:59 EST 2025 Mon Jul 21 09:14:44 EDT 2025 Thu Apr 24 23:10:34 EDT 2025 Tue Jul 01 02:23:53 EDT 2025 Wed Aug 20 07:25:12 EDT 2025 Sun Sep 21 06:27:04 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	Tumor Chromosome Nervous system diseases Prognosis Glioma Central nervous system disease
Language	English
License	http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4223-c29febac3fb7b3bc02ed7b2c9fbd292040b9ecffc3f9514fcad3434de8d19d633
Notes	ark:/67375/WNG-6KM9HHZ3-5 istex:5A248DCE91AFB2CC85ED87B01813260CC56C8F44 Ligue nationale contre le cancer ArticleID:ANA20543 Délégation à la Recherche Clinique - No. AP-HP; No. MUL03012 Fondation de France - No. 2002008957 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	16049942
PQID	17345318
PQPubID	23462
PageCount	5
ParticipantIDs	proquest_miscellaneous_68433002 proquest_miscellaneous_17345318 pubmed_primary_16049942 pascalfrancis_primary_17082262 crossref_primary_10_1002_ana_20543 crossref_citationtrail_10_1002_ana_20543 wiley_primary_10_1002_ana_20543_ANA20543 istex_primary_ark_67375_WNG_6KM9HHZ3_5
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	August 2005
PublicationDateYYYYMMDD	2005-08-01
PublicationDate_xml	– month: 08 year: 2005 text: August 2005
PublicationDecade	2000
PublicationPlace	Hoboken
PublicationPlace_xml	– name: Hoboken – name: United States
PublicationTitle	Annals of neurology
PublicationTitleAlternate	Ann Neurol
PublicationYear	2005
Publisher	Wiley Subscription Services, Inc., A Wiley Company Willey-Liss
Publisher_xml	– name: Wiley Subscription Services, Inc., A Wiley Company – name: Willey-Liss
References	Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-3138. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201. Jeuken JW, Sprenger SH, Boerman RH, et al. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. J Pathol 2001; 194: 81-87. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-2084. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001; 60: 863-871. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 52: 2987-2990. Kleihues. Pathology and genetics. Tumours of the nervous system.WHO classification of tumours. Lyon, France: IARC Press, 2000. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 2004; 108: 49-56. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-556. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52: 316-324. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098-1104. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20: 2267-2276. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-319. 1994; 145 2004; 22 2001; 60 2002; 161 2001; 194 2002; 52 2000 2002; 20 2002; 8 1997; 56 1996; 36 2004; 108 1992; 52 Reifenberger J (e_1_2_6_3_2) 1994; 145 Ueki K (e_1_2_6_7_2) 2002; 8 von Deimling A (e_1_2_6_2_2) 1992; 52 Kleihues (e_1_2_6_4_2) 2000 e_1_2_6_8_2 e_1_2_6_9_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_14_2 e_1_2_6_15_2
References_xml	– reference: Kleihues. Pathology and genetics. Tumours of the nervous system.WHO classification of tumours. Lyon, France: IARC Press, 2000. – reference: von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 52: 2987-2990. – reference: Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56: 1098-1104. – reference: Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-319. – reference: Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22: 3133-3138. – reference: Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201. – reference: Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-556. – reference: Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20: 2267-2276. – reference: He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001; 60: 863-871. – reference: Jeuken JW, Sprenger SH, Boerman RH, et al. Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. J Pathol 2001; 194: 81-87. – reference: Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-2084. – reference: Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 2004; 108: 49-56. – reference: Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-1190. – reference: Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52: 316-324. – volume: 22 start-page: 3133 year: 2004 end-page: 3138 article-title: Temozolomide as initial treatment for adults with low‐grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions publication-title: J Clin Oncol – volume: 20 start-page: 2267 year: 2002 end-page: 2276 article-title: Prospective randomized trial of low‐ versus high‐dose radiation therapy in adults with supratentorial low‐grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study publication-title: J Clin Oncol – volume: 108 start-page: 49 year: 2004 end-page: 56 article-title: Population‐based study on incidence, survival rates, and genetic alterations of low‐grade diffuse astrocytomas and oligodendrogliomas publication-title: Acta Neuropathol (Berl) – volume: 20 start-page: 2076 year: 2002 end-page: 2084 article-title: Prognostic factors for survival in adult patients with cerebral low‐grade glioma publication-title: J Clin Oncol – volume: 194 start-page: 81 year: 2001 end-page: 87 article-title: Subtyping of oligo‐astrocytic tumours by comparative genomic hybridization publication-title: J Pathol – volume: 52 start-page: 316 year: 2002 end-page: 324 article-title: Randomized trial on the efficacy of radiotherapy for cerebral low‐grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis publication-title: Int J Radiat Oncol Biol Phys – volume: 145 start-page: 1175 year: 1994 end-page: 1190 article-title: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p publication-title: Am J Pathol – year: 2000 – volume: 36 start-page: 549 year: 1996 end-page: 556 article-title: A randomized trial on dose‐response in radiation therapy of low‐grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844 publication-title: Int J Radiat Oncol Biol Phys – volume: 8 start-page: 196 year: 2002 end-page: 201 article-title: Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors publication-title: Clin Cancer Res – volume: 161 start-page: 313 year: 2002 end-page: 319 article-title: Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets publication-title: Am J Pathol – volume: 52 start-page: 2987 year: 1992 end-page: 2990 article-title: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma publication-title: Cancer Res – volume: 60 start-page: 863 year: 2001 end-page: 871 article-title: Glioblastomas with an oligodendroglial component: a pathological and molecular study publication-title: J Neuropathol Exp Neurol – volume: 56 start-page: 1098 year: 1997 end-page: 1104 article-title: Molecular genetic evidence for subtypes of oligoastrocytomas publication-title: J Neuropathol Exp Neurol – ident: e_1_2_6_10_2 doi: 10.1002/path.837 – ident: e_1_2_6_6_2 doi: 10.1016/S0002-9440(10)64183-1 – volume-title: Pathology and genetics. Tumours of the nervous system.WHO classification of tumours year: 2000 ident: e_1_2_6_4_2 – ident: e_1_2_6_8_2 doi: 10.1007/s00401-004-0861-z – ident: e_1_2_6_5_2 doi: 10.1093/jnen/60.9.863 – ident: e_1_2_6_9_2 doi: 10.1097/00005072-199710000-00003 – volume: 145 start-page: 1175 year: 1994 ident: e_1_2_6_3_2 article-title: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p publication-title: Am J Pathol – ident: e_1_2_6_13_2 doi: 10.1016/S0360-3016(96)00352-5 – ident: e_1_2_6_15_2 doi: 10.1200/JCO.2004.10.169 – ident: e_1_2_6_12_2 doi: 10.1200/JCO.2002.08.121 – ident: e_1_2_6_11_2 doi: 10.1200/JCO.2002.09.126 – volume: 8 start-page: 196 year: 2002 ident: e_1_2_6_7_2 article-title: Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors publication-title: Clin Cancer Res – ident: e_1_2_6_14_2 doi: 10.1016/S0360-3016(01)02692-X – volume: 52 start-page: 2987 year: 1992 ident: e_1_2_6_2_2 article-title: p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma publication-title: Cancer Res
SSID	ssj0009610
Score	2.124627
Snippet	Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor (EGFR) gene amplification, and p53 expression was... Search for loss of heterozygosity on chromosomes 1p, 9p, 10q, and 19q, epidermal growth factor receptor ( EGFR ) gene amplification, and p53 expression was...
SourceID	proquest pubmed pascalfrancis crossref wiley istex
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	322
SubjectTerms	Adolescent Adult Aged Antineoplastic agents Biological and medical sciences Brain Neoplasms - genetics Brain Neoplasms - pathology Chemotherapy Chromosome Deletion Chromosomes, Human, Pair 1 Chromosomes, Human, Pair 19 Female Glioma - genetics Glioma - pathology Humans Immunohistochemistry - methods Loss of Heterozygosity Male Medical sciences Middle Aged Molecular Biology - methods Neurology Pharmacology. Drug treatments Tumors of the nervous system. Phacomatoses
Title	Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas
URI	https://api.istex.fr/ark:/67375/WNG-6KM9HHZ3-5/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.20543 https://www.ncbi.nlm.nih.gov/pubmed/16049942 https://www.proquest.com/docview/17345318 https://www.proquest.com/docview/68433002
Volume	58
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1ba9RAFMeHUkF80XrtWq2DiPQlbZKZTJL6tKg1KLsPYrGIMMy1lG6TshcVn_oR-hn7STxnstllpQXxLZB_Bs7MmcxJ5szvEPIqcaZQOZ7MFcJGHGLWSGXeRTkzsBzqwolwXGwwFNUh_3iUHa2RN91ZmJYPsfjhhjMjvK9xgis92VtCQ1WN2KCMI-kzYQK5-e8-L9FRpQgkAtxmi7KE8Y4qFKd7iydX1qJb2K2_MDdSTaB7fFvX4rrAczWODQvRwT3yvTOhzT853Z1N9a75_Rfd8T9t3CB35wEq7bcedZ-sufoBuT2Yb8E_JBXidM-aSXPmaHJOR2DYPu1Tr36AM-mRo5jxVTeIf6ZtMR96UoPs59XF5fFYWUePRyeYlPSIHB68__K2iublGCLDIYiITFp6p5VhXueaaROnzuY6NaXXFmte8ViXzngPAgjbuDfKMs64dYVNSisYe0zW66Z2m4RanmrNURYrzuJYGZBDc1ylWeET3SM73cBIM2eVY8mMkWwpy6mEnpGhZ3rk5UJ63gI6rhO9DqO7UKjxKWa05Zn8OvwgxadBWVXfmMx6ZHtl-JdN5ojGF2mPvOj8QcJExN0VVbtmNgEF4_BCK25WiIIzMBbaeNI60rJ1gV-eHO7sBHe42RLZH_bDxdN_l26ROwE4G9IWn5H16XjmnkMoNdXbYc78AeWPGX4
linkProvider	Wiley-Blackwell
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB7SBNpekv53kzYRpZRcnNiWLNull6UkdZvsHkpCQyEISZZCyMYO-9OWnvoIfcY-STXyepcNCZTeDP48MNKMNNaMvgF4HRmdyRRv5nJeBszFrIFMrAlSqt12qDLD_XWxXp8Xx-zTSXKyBO_auzANP8TswA09w6_X6OB4IL07Zw2VFfIGJYzegRWfn8OQ6POcPCrnnosAE21BElHW8gqF8e7s04XdaAUH9gdWR8qRGyDbdLa4KfRcjGT9VrS_BqetEk0FysXOZKx29M9r_I7_q-UDWJ3GqKTbGNVDWDLVI7jbm2bhH0OBjLqX9ai-NCS6IgOn2VvSJVZ-c_akBoZg0VdVIwM0afr5kPPKwb7_-fX7bChLQ84G51iX9ASO9_eO3hfBtCNDoJmLIwId59YoqalVqaJKh7EpUxXr3KoS216xUOVGW-sALnJjVsuSMspKk5VRXnJKn8JyVVfmOZCSxUoxhIWS0TCU2sGdOCbjJLOR6sB2OzNCT-nKsWvGQDREy7FwIyP8yHTg1Qx61XB03AR646d3hpDDCyxqSxPxpf9B8INeXhRfqUg6sLkw_3ORKbLj87gDW61BCOeLmGCRlaknI4egzK1p2e0InjHqlHUynjWWNJfO8eeTuTfb3h5u10R0-13_sP7v0C24Vxz1DsXhx_7BBtz3_LO-ivEFLI-HE_PSRVZjtekd6C9tDB2c
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEB5qC8Uv1nevahtEpF_SJtnNJtFPh3pG6x0iFksRln0tpdfkuBcVP_kT_I3-Emc3lztOWhC_BfJkYGZnMpPs7DMAT2OjcpG5k7mM6ZBizRqK1JowIwrTocwN88fF-gNWHtF3x-nxGrxoz8I0_BCLH24uMvz72gX4SNuDJWmoqBxtUErJNdigDNOkq4g-LrmjCuapCNw-W5jGhLa0QlFysHh0JRltOLt-d82RYoL2sc1gi8sqz9VC1mei3hZ8aXVoGlDO92dTua9-_EXv-J9K3oQb8wo16DYudQvWTHUbNvvzPfg7UDo-3Yt6Ul-YIB4FQ1TsedANrPiK3iSHJnAtX1Xt-J-DZppPcFYh7Nvvn79Ox0Kb4HR45rqS7sJR7_Wnl2U4n8cQKopVRKiSwhopFLEyk0SqKDE6k4kqrNRu6BWNZGGUtQjAuo1aJTShhGqT67jQjJB7sF7VlXkAgaaJlNTBIkFJFAmFcBRHRZLmNpYd2GsXhqs5WbmbmTHkDc1ywtEy3FumA08W0FHD0HEZ6Jlf3QVCjM9dS1uW8s-DN5wd9ouyPCE87cDOyvIvRWaOG58lHdht_YFjJLrtFVGZejZBBKH4RsuvRrCcElQWZdxvHGkpnblPT4p39rw7XK0J7w66_mL736G7sPnhVY-_fzs4fAjXPfmsb2F8BOvT8cw8xrJqKnd8-PwBA9AcSw
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chromosome+1p+loss%3A+A+favorable+prognostic+factor+in+low-grade+gliomas&rft.jtitle=Annals+of+neurology&rft.au=Kujas%2C+Mich%C3%A8le&rft.au=Lejeune%2C+Julie&rft.au=Benouaich-Amiel%2C+Alexandra&rft.au=Crini%C3%A8re%2C+Emmanuelle&rft.date=2005-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0364-5134&rft.eissn=1531-8249&rft.volume=58&rft.issue=2&rft.spage=322&rft.epage=326&rft_id=info:doi/10.1002%2Fana.20543&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_6KM9HHZ3_5
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-5134&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-5134&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-5134&client=summon